Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|May 19, 2020

Supplements and Featured Publications

  • AJMC Profiles in Care: Boehringer Ingelheim and UPMC Health Plan: A Value-Driven Partnership Focused on Outcomes in Diabetes and Cardiovascular Disease

Boehringer Ingelheim and UPMC Health Plan: A Value-Driven Partnership Focused on Outcomes in Diabetes and Cardiovascular Disease

This AJMC® Profiles in Care stakeholder case study highlights the development and management of an innovative value-based partnership between Boehringer Ingelheim and UPMC Health Plan, which focuses on outcomes in diabetes and cardiovascular disease, including the rationale for participation in the partnership, areas of focus, expected benefits, and organizational challenges and solutions.

Download PDF: Boehringer Ingelheim and UPMC Health Plan: A Value-Driven Partnership Focused on Outcomes in Diabetes and Cardiovascular Disease

Related to this article

View more
Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Read more
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel. | Image: LinkedIn
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Read more